<DOC>
	<DOCNO>NCT01949311</DOCNO>
	<brief_summary>This open label extension study patient participate placebo-controlled dupilumab atopic dermatitis ( AD ) trial . The study primarily evaluate long term safety ( adverse event ) immunogenicity . Efficacy parameter base Investigator Global Assessment ( IGA ) , Eczema Area Severity Index ( EASI ) Pruritus Numerical Rating Scale ( NRS ) .</brief_summary>
	<brief_title>Open-label Study Dupilumab ( REGN668/SAR231893 ) Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>The inclusion criterion include , limited , follow : 1 . Participation prior clinical trial dupilumab AD meet one following : 1 . Received study treatment adequately complete assessment require treatment followup period parent study ( except study list b ) define parent protocol 2 . Received study treatment one study complete last patient last visit : R668AD0914 , R668AD1026 , R668AD1117 , R668AD1021 , R668AD1121 , R668AD1307 irrespective duration participation . 3 . Underwent screen R668AD1334 ( Liberty AD SOLO 1 ) R668AD1416 ( Liberty AD SOLO 2 ) , could randomize due randomization closure . 2 . Willing able comply clinic visit studyrelated procedure 3 . Able understand complete studyrelated questionnaire 4 . Provide sign informed consent The exclusion criterion include , limited , follow : 1 . Patients , participation previous dupilumab clinical trial , develop serious adverse event ( SAE ) deem related dupilumab* , opinion investigator medical monitor could indicate continue treatment dupilumab may present unreasonable risk patient . 2 . Patients , participation previous dupilumab clinical trial , develop AE deem related dupilumab* lead study treatment discontinuation , opinion investigator medical monitor could indicate continue treatment dupilumab may present unreasonable risk patient . 3 . Conditions previous dupilumab study consistent protocoldefined criterion permanent study drug discontinuation , deem related dupilumab* lead investigator sponsorinitiated withdrawal patient study ( eg , noncompliance , inability complete study assessment , etc. ) . *Note exclusion criterion # 1 , 2 , 3 : In study still blind , condition deem related study treatment consider related dupilumab . 4 . Treatment investigational drug , dupilumab , within 8 week within 5 halflives ( know ) , whichever longer , baseline visit 5 . Pregnant breastfeed woman , plan become pregnant breastfeed patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>